Literature DB >> 15562034

Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects.

Sangeeta R Kashyap1, Linda J Roman, Jennifer Lamont, Bettie Sue S Masters, Mandeep Bajaj, Swangjit Suraamornkul, Renata Belfort, Rachele Berria, Dean L Kellogg, Yanjuan Liu, Ralph A DeFronzo.   

Abstract

Type 2 diabetes is an insulin-resistant state characterized by hyperinsulinemia and accelerated atherosclerosis. In vitro and in vivo studies in rodents have suggested that nitric oxide generation plays an important role in glucose transport and insulin action. We determined nitric oxide synthase (NOS) activity in skeletal muscle of 10 type 2 diabetic (hemoglobin A(1C) = 6.8 +/- 0.1%) and 11 control subjects under basal conditions and during an 80 mU/m(2).min euglycemic insulin clamp performed with vastus lateralis muscle biopsies before and after 4 h of insulin. In diabetics, insulin-stimulated glucose disposal (Rd) was reduced by 50%, compared with controls (5.4 +/- 0.3 vs. 10.4 +/- 0.5 mg/kg.min, P < 0.01). Basal NOS activity was markedly reduced in the diabetic group (101 +/- 33 vs. 457 +/- 164 pmol/min.mg protein, P < 0.05). In response to insulin, NOS activity increased 2.5-fold in controls after 4 h (934 +/- 282 pmol/min.mg protein, P < 0.05 vs. basal), whereas insulin failed to stimulate NOS activity in diabetics (86 +/- 28 pmol/min.mg protein, P = NS from basal). Basal NOS protein content in muscle was similar in controls and diabetics and did not change following insulin. In controls, insulin-stimulated NOS activity correlated inversely with fasting plasma insulin concentration (r = -0.58, P = 0.05) and positively with Rd (r = 0.71, P = 0.03). In control and diabetic groups collectively, Rd correlated with insulin-stimulated NOS activity (r = 0.52, P = 0.02). We conclude that basal and insulin-stimulated muscle NOS activity is impaired in well-controlled type 2 diabetic subjects, and the defect in insulin-stimulated NOS activity correlates closely with the severity of insulin resistance. These results suggest that impaired NOS activity may play an important role in the insulin resistance in type 2 diabetic individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562034     DOI: 10.1210/jc.2004-0745

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  Disturbance of regulation of NO synthase activity by peptides of insulin family in rat skeletal muscles in streptozotocin model of neonatal type 2 diabetes mellitus.

Authors:  L A Kuznetsova; O V Chistyakova; V M Bondareva; T S Sharova; M N Pertseva
Journal:  Dokl Biochem Biophys       Date:  2010 May-Jun       Impact factor: 0.788

2.  Progressive hyperglycemia across the glucose tolerance continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide bioavailability.

Authors:  Thomas P J Solomon; Jacob M Haus; Yanjun Li; John P Kirwan
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

3.  Changes in microvascular density differentiate metabolic health outcomes in monkeys with prior radiation exposure and subsequent skeletal muscle ECM remodeling.

Authors:  K M Fanning; B Pfisterer; A T Davis; T D Presley; I M Williams; D H Wasserman; J M Cline; K Kavanagh
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-07-12       Impact factor: 3.619

4.  Neuronal nitric oxide synthase mediates insulin- and oxidative stress-induced glucose uptake in skeletal muscle myotubes.

Authors:  Dean L Kellogg; Karen M McCammon; Kathryn S Hinchee-Rodriguez; Martin L Adamo; Linda J Roman
Journal:  Free Radic Biol Med       Date:  2017-06-27       Impact factor: 7.376

Review 5.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

6.  Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans.

Authors:  Amale A Lteif; Angie D Fulford; Robert V Considine; Inessa Gelfand; Alain D Baron; Kieren J Mather
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-28       Impact factor: 4.310

Review 7.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.

Authors:  R A DeFronzo
Journal:  Diabetologia       Date:  2010-04-02       Impact factor: 10.122

8.  Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy.

Authors:  Paolo Tessari; Diego Cecchet; Alessandra Cosma; Monica Vettore; Anna Coracina; Renato Millioni; Elisabetta Iori; Lucia Puricelli; Angelo Avogaro; Monica Vedovato
Journal:  Diabetes       Date:  2010-05-18       Impact factor: 9.461

9.  NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  A Y Chu; J Coresh; D E Arking; J S Pankow; G F Tomaselli; A Chakravarti; W S Post; P H Spooner; E Boerwinkle; W H L Kao
Journal:  Diabetologia       Date:  2009-11-27       Impact factor: 10.122

10.  Insulin reduces plasma arginase activity in type 2 diabetic patients.

Authors:  Sangeeta R Kashyap; Abigail Lara; Renliang Zhang; Young Mi Park; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2007-10-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.